Recent Company News

• 07:06 AM ET Aug 10, 2026
  

  Grifols announces the completion of the clinical portion of SPARTA study; Top line results expected by the end of 2026 (€10.04, -0.14)

• 02:23 PM ET Jul 28, 2026
  

  Transcript Intelligence: Grifols Q2 Earnings Guidance

• 02:23 PM ET Jul 28, 2026
  

  Transcript Intelligence: Grifols Q2 Earnings Themes

• 02:23 PM ET Jul 28, 2026
  

  Transcript Intelligence: Grifols Q2 Earnings Q&A

• 11:54 AM ET Jul 28, 2026
  

  StreetAccount Metrics Recap - Grifols Q2 Earnings (€9.99, 0.00)

• 11:54 AM ET Jul 28, 2026
  

  Grifols reports Q2 net income €155M vs consensus €120.2M; on track to deliver its 2026 guidance (€9.99, 0.00)

• 06:22 AM ET Jul 27, 2026
  

  StreetAccount Consensus Metrics Preview - Grifols Q2 Earnings (€9.78, +0.13)

• 07:08 PM ET Jul 21, 2026
  

  President Trump states tariff on generic drugs will stay at 0% for 2 years then rise to 100% - Truth Social

• 08:01 AM ET Jul 16, 2026
  

  Grifols doses first patients in two phase 3 trials to expand indications of flagship immunoglobulins (€9.00, -0.02)

• 02:49 PM ET Jul 06, 2026
  

  FTC grants antitrust clearance for transaction involving Grifols and holder Flat Footed (€9.06, 0.00)